Quarterly Report · 10-Q
SeaStar Medical Holding Corporation
ICUNASDAQEQUITYCurrent
Quarterly Report
Company context
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗